SCHEMBL4167301

SCHEMBL4167301

Cc1cc(Nc2cnc(-c3ccc(F)c(NC(C)C)c3)c(N)n2)n[nH]1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 13/20 0.44
▸ JAK3 P52333 13/20 0.44
▸ NTRK1 P04629 5/20 0.42
▸ CDK2 P24941 3/20 0.42
▸ AURKB Q96GD4 3/20 0.42
▸ STAT5B P51692 1/20 0.41
▸ RET P07949 3/20 0.38
▸ FLT3 P36888 2/20 0.38
▸ PTK2B Q14289 2/20 0.38
▸ MUSK O15146 1/20 0.38
▸ LCK P06239 1/20 0.38
▸ FGFR3 P22607 1/20 0.38
▸ CCNE1 P24864 1/20 0.38
▸ AURKA O14965 2/20 0.37
▸ PLK4 O00444 1/20 0.37
▸ STK10 O94804 1/20 0.37
▸ PAK4 O96013 1/20 0.37
▸ FGFR1 P11362 1/20 0.37
▸ FER P16591 1/20 0.37
▸ CSNK2A2 P19784 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4159458 0.90 JAK2 (0.41) JAK2JAK3NTRK1CDK2AURKB
SCHEMBL4170573 0.88 NTRK1 (0.40) JAK2JAK3NTRK1CDK2AURKB
SCHEMBL4179956 0.83 JAK2 (0.43) JAK2JAK3NTRK1CDK2AURKB
SCHEMBL4303875 0.82 JAK2 (0.49) JAK2JAK3NTRK1CDK2AURKB
SCHEMBL4162005 0.82 JAK2 (0.39) JAK2JAK3NTRK1CDK2AURKB
SCHEMBL4168663 0.81 AURKB (0.43) JAK2JAK3NTRK1CDK2AURKB
SCHEMBL4169624 0.80 ITK (0.43) JAK2JAK3NTRK1CDK2AURKB
SCHEMBL4179012 0.80 MEN1 (0.46) JAK2JAK3NTRK1RETAURKA
SCHEMBL4167808 0.78 ITK (0.40) JAK2JAK3NTRK1CDK2AURKB
SCHEMBL4168909 0.78 IKBKB (0.46) JAK2JAK3NTRK1AURKBRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 — — US claimed
WO-2009089042-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC (US) 2009-07-16 — — WO claimed
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH SIGNAL PHARMACEUTICALS, LLC 2009-10-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270418-A1 PYRAZOLE PYRAZINE AMINE COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS THEREOF AND METHODS OF TREATMENT THEREWITH MAP3K1, MAP3K15, MAP3K5 JAK2 39/4885JAK3 35/4885NTRK1 2610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback